Global Crohn’s Disease Market Segmentation, By Procedures (Colonoscopy, Flexible Sigmoidoscopy, and Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Capsule Endoscopy, Double-Balloon Endoscopy, and Small Bowel Imaging), Therapeutic type (Non-surgical and Surgical), End User (Hospitals and Clinics, Research Institutes, Diagnostic Centres, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, and Others) – Industry Trends and Forecast to 2031.
Crohn’s Disease Market Analysis
The Crohn's disease market is experiencing dynamic growth, driven by advancements in therapeutic options and increasing prevalence. Developments in the market include the introduction of biologics and targeted therapies that offer more effective management of the disease. For instance, the approval of new monoclonal antibodies such as Vedolizumab and Ustekinumab has significantly improved patient outcomes by targeting specific inflammatory pathways. Additionally, pipeline drugs and ongoing clinical trials are exploring novel treatment approaches, such as oral JAK inhibitors and personalized medicine strategies. The market is also witnessing increased investment in research and development, with pharmaceutical companies and biotech firms focusing on advanced therapies to address unmet needs. This growing emphasis on innovation, coupled with rising awareness and improved diagnostic techniques, is expected to drive the market forward, offering new hope for patients and expanding treatment options.
Crohn’s Disease Market Size
The global Crohn’s disease market size was valued at USD 9.85 billion in 2023 and is projected to reach USD 13.17 billion by 2031, with a CAGR of 3.70% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Crohn’s Disease Market Trends
“Growing Focus on Personalized Medicine”
The Crohn’s disease market is evolving with several key trends shaping its landscape. One notable trend is the growing focus on personalized medicine, which tailors treatment plans based on individual patient profiles. For instance, recent advancements in genomic research have enabled the development of targeted therapies that address specific genetic mutations associated with Crohn's disease. Biologics such as anti-TNF agents and newer therapies such as Janus Kinase (JAK) inhibitors are being refined to provide more effective and individualized treatment options. This trend is driven by a need for treatments that offer better efficacy and fewer side effects compared to traditional therapies. Additionally, the rise of digital health technologies, including mobile apps for symptom tracking and telemedicine consultations, is improving patient management and adherence. These developments reflect a shift towards more precise and patient-centered approaches in the Crohn’s disease market, enhancing treatment outcomes and overall patient care.
Report Scope and Crohn’s Disease Market Segmentation
|
Attributes
|
Crohn’s Disease Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Key Market Players
|
GSK plc. (U.K.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Lilly (U.S.), AstraZeneca (U.K.), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Bristol-Myers Squibb Company (U.S.), Sanofi (France), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), AbbVie Inc. (U.S.), Janssen Global Services, LLC (U.S.), UCB S.A. (Belgium), Ferring (Switzerland), Tillotts Pharma AG (Switzerland), Merck & Co., Inc. (U.S.), and Amgen Inc. (U.S.).
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Crohn’s Disease Market Definition
Crohn's disease is a chronic inflammatory bowel disease (IBD) characterized by inflammation of the digestive tract, which can occur anywhere from the mouth to the anus. It commonly affects the ileum (the last part of the small intestine) and the colon (the large intestine). The inflammation caused by Crohn's disease can lead to symptoms such as abdominal pain, diarrhea, weight loss, and fatigue. The exact cause of Crohn's disease is not fully understood, but it is believed to involve a combination of genetic, environmental, and immune system factors. The condition is marked by periods of flare-ups and remission, and while there is no cure, treatments are available to manage symptoms and improve quality of life.
Crohn’s Disease Market Dynamics
Drivers
- Increasing Prevalence of Crohn’s Disease
The increasing prevalence of Crohn’s disease is a significant driver of market growth, reflecting a rising global incidence of this chronic inflammatory condition. According to the Crohn's & Colitis Foundation, approximately 3 million individuals in the United States alone are affected by inflammatory bowel diseases, including Crohn’s disease. Such growing patient population underscores the urgent need for effective treatment options. As the number of diagnosed cases continues to climb, driven by factors such as improved diagnostic techniques and greater disease awareness, there is a corresponding surge in demand for innovative therapies. This heightened demand is prompting pharmaceutical companies and biotech firms to accelerate the development of new treatments, further fueling market expansion and improving the overall management of Crohn’s disease.
- Increasing Application of Stem Cells
The increasing application of stem cells in treating diseases is becoming a notable driver for the Crohn's disease market. Stem cell therapy presents new possibilities for managing and potentially curing Crohn's disease by fostering tissue repair and modulating immune responses. For instance, recent studies have investigated the use of mesenchymal stem cells (MSCs) for Crohn's disease, revealing that MSCs can diminish inflammation and facilitate healing in the gastrointestinal tract. The potential of stem cell therapy to target the root causes of the disease and improve treatment outcomes is fueling both interest and investment in this field. Such growing focus on stem cell research is contributing to the market's expansion and holds promise for advancing more effective strategies for managing Crohn's disease.
Opportunities
- Increasing Development of Advanced Imaging Techniques
The development and implementation of advanced imaging techniques, such as high-resolution magnetic resonance enterography (MRE) and capsule endoscopy, are significantly improving the accuracy and early detection of Crohn’s Disease. Additionally, the integration of novel biomarkers, such as fecal calprotectin levels and genetic markers, is enhancing diagnostic precision and differentiation from other inflammatory bowel diseases. Companies that innovate and offer these advanced diagnostic tools can tap into a growing market need for more effective early detection and monitoring solutions. By improving diagnostic capabilities, these initiatives not only facilitate earlier and more accurate diagnosis but also drive demand for targeted treatments, thereby expanding market opportunities for diagnostic and therapeutic solutions in the Crohn’s disease sector.
- Growing Awareness and Advocacy
Growing awareness and advocacy for Crohn’s disease play a crucial role in enhancing disease management and fostering proactive treatment approaches. Efforts by patient advocacy groups, such as the Crohn's & Colitis Foundation, have significantly raised public awareness and educated both patients and healthcare providers about the condition. For instance, “Take Steps” walk, an initiative by the Crohn's & Colitis Foundation, which raises millions of dollars annually to support research and patient services. Such advocacy efforts not only contribute to advancements in treatment but also improve patient access to emerging therapies and resources, thereby driving overall market growth and improving outcomes for those affected by Crohn’s disease.
Restraints/Challenges
- High Cost of Treatments
The high cost of treatments is a significant challenge in the Crohn's disease market, particularly with advanced therapies such as biologics and new targeted drugs. Medications such as Adalimumab and Ustekinumab, although effective, come with substantial price tags that can be prohibitive for many patients. High costs limits accessibility, especially for those in low-income or underinsured populations, who may find it difficult to afford these essential treatments. The financial burden extends beyond individual patients to healthcare systems, which face increased costs and budget constraints. Consequently, widespread adoption of these advanced therapies can be hindered, impacting overall market growth.
- High Cost of Advanced Crohn’s Disease
The high cost of advanced Crohn’s disease poses a significant challenge in the global market, particularly for products incorporating antimicrobial properties or cutting-edge materials. These advanced dressings, designed to enhance wound healing and prevent infections, often come with a higher price tag due to the sophisticated technologies and materials involved. For instance, antimicrobial dressings that contain silver or honey can be substantially more expensive than traditional options. Such elevated cost can limit accessibility, especially in low-resource settings where healthcare budgets are constrained and insurance coverage may be insufficient. Consequently, patients in economically disadvantaged regions or those without adequate insurance may face difficulties obtaining these advanced dressings, potentially impacting their treatment outcomes and overall market growth.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Crohn’s Disease Market Scope
The market is segmented on the basis of procedures, therapeutic type, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Procedures
- Colonoscopy
- Flexible Sigmoidoscopy
- Computerized Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Capsule Endoscopy
- Double-Balloon Endoscopy
- Small Bowel Imaging
Therapeutic Type
- Non-surgical
- Surgical
End User
- Hospitals and Clinics
- Research Institutes
- Diagnostic Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online
- Others
Crohn’s Disease Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, procedures, therapeutic type, end user, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America leads the Crohn's Disease market due to its advanced healthcare infrastructure, robust research and development capabilities of pharmaceutical companies, and swift adoption of cutting-edge healthcare technologies. The region's high prevalence of gastrointestinal disorders is also driving industry trends and market growth.
The Asia-Pacific region is expected to experience the highest growth rate during the forecast period, driven by increased investments in healthcare infrastructure and enhanced engagement of regulatory bodies in research and development activities. This growth is further supported by the expanding healthcare needs of a rapidly growing population and the region's ongoing efforts to modernize medical facilities and services.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Crohn’s Disease Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Crohn’s Disease Market Leaders Operating in the Market Are:
- GSK plc. (U.K.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Lilly (U.S.)
- AstraZeneca (U.K.)
- Pfizer Inc. (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Bristol-Myers Squibb Company (U.S.)
- Sanofi (France)
- Johnson & Johnson Services, Inc. (U.S.)
- Bayer AG (Germany)
- AbbVie Inc. (U.S.)
- Janssen Global Services, LLC (U.S.)
- UCB S.A. (Belgium)
- Ferring (Switzerland)
- Tillotts Pharma AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Amgen Inc. (U.S.)
Latest Developments in Crohn’s Disease Market
- In April 2022, The Crohn's and Colitis Foundation has funded to Microbiotica under its Inflammatory Bowel Disease Ventures Program. The funding will help Microbiotica accelerate its research and contribute to new therapeutic solutions for managing Crohn's disease and ulcerative colitis
- In April 2022, Engitix expanded its partnership with Takeda to focus on discovering and developing innovative therapeutics for fibrostenotic inflammatory bowel diseases, such as Crohn's disease. This extended collaboration aims to leverage Engitix's expertise in tissue modeling and Takeda's extensive therapeutic development capabilities to address unmet needs in managing these challenging conditions
SKU-